APA (7th ed.) Citation

Hauswald, H., Jensen, A., Krauß, J., Haselmann, R., Lossner, K., Münter, M., & Debus, J. (2018). Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clinical and translational radiation oncology, 13, . https://doi.org/10.1016/j.ctro.2018.09.005

Chicago Style (17th ed.) Citation

Hauswald, Henrik, Alexandra Jensen, Jürgen Krauß, Renate Haselmann, Karen Lossner, Marc Münter, and Jürgen Debus. "Phase II Study of Induction Chemotherapy with Docetaxel, Cisplatin, 5-fluorouracil Followed by Radioimmunotherapy with Cetuximab and Intensity-modulated Radiotherapy in Combination with a Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx." Clinical and Translational Radiation Oncology 13 (2018). https://doi.org/10.1016/j.ctro.2018.09.005.

MLA (9th ed.) Citation

Hauswald, Henrik, et al. "Phase II Study of Induction Chemotherapy with Docetaxel, Cisplatin, 5-fluorouracil Followed by Radioimmunotherapy with Cetuximab and Intensity-modulated Radiotherapy in Combination with a Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx." Clinical and Translational Radiation Oncology, vol. 13, 2018, https://doi.org/10.1016/j.ctro.2018.09.005.